# Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

> **NCT05215847** · PHASE2 · COMPLETED · sponsor: **Aardvark Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Bariatric Surgery
- Obesity
- Weight Gain

## Interventions

- **DRUG:** ARD-101

## Key facts

- **NCT ID:** NCT05215847
- **Lead sponsor:** Aardvark Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-01
- **Primary completion:** 2023-02-03
- **Final completion:** 2023-02-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215847, "Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05215847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*